Design and conduct of a provider survey to determine a clinically persuasive effect size in planning VA Cooperative Study #590 (Li+)
| Autor: | Erick Flores, Keri Hannagan, Natalie Morgenstern, Ryan Ferguson, Matthew H. Liang, Soe Soe Thwin, Ira R. Katz, Kelly M. Harrington |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Effect size Article 03 medical and health sciences 0302 clinical medicine Controlled clinical trial medicine In patient 030212 general & internal medicine Bipolar disorder Psychiatry Depression (differential diagnoses) Pharmacology Estimation lcsh:R5-920 business.industry 05 social sciences Reduction rate 050301 education General Medicine medicine.disease Response bias Clinical Practice Clinical trial Clinical survey Clinicians' opinions Sample size estimation lcsh:Medicine (General) business 0503 education |
| Zdroj: | Contemporary Clinical Trials Communications Contemporary Clinical Trials Communications, Vol 4, Iss C, Pp 149-154 (2016) |
| ISSN: | 2451-8654 |
| Popis: | Background The estimation of an effect size is an important step in designing an adequately powered, feasible clinical trial intended to change clinical practice. During the planning phase of VA Cooperative Study #590, “Double-Blind Placebo-Controlled Study of Lithium for Preventing Repeated Suicidal Self-Directed Violence in Patients with Depression or Bipolar Disorder (Li+),” it was not clear what effect size would be considered large enough to influence prescribing behavior among practicing clinicians. Methods We conducted an online survey of VA psychiatrists to assess their interest in the study question, their clinical experience with lithium, and their opinion about what suicide reduction rate would change their prescribing habits. The 9-item survey was hosted on SurveyMonkey© and VA psychiatrists were individually emailed an invitation to complete an anonymous online survey. Three email waves were sent over three weeks. Results Overall, 862 of 2713 VA psychiatrists (response rate = 31.8%) responded to the anonymous survey. 74% of the respondents would refer a patient to the proposed trial, 9% would not, and 17% were unsure. Presented with suicide reduction rates in 10% increments ranging from 10 to 100%, 61% of respondents indicated that they would use lithium if suicide attempts were reduced by at least 40%; 83% would use lithium if it reduced attempts by at least 50%. Conclusions Even with the limitations of response bias and the reliability of responses on future prescribing behavior, a survey of potential users of a clinical trial's results offers a convenient, empirical method for determining and justifying clinically relevant effect sizes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|